Document 0845
 DOCN  M9470845
 TI    Rapid decrease in unintegrated human immunodeficiency virus DNA after
       the initiation of nucleoside therapy.
 DT    9409
 AU    Donovan RM; Bush CE; Smereck SM; Baxa DM; Markowitz NP; Saravolatz LD;
       Department of Internal Medicine, Henry Ford Hospital, Detroit,; Michigan
       48202.
 SO    J Infect Dis. 1994 Jul;170(1):202-5. Unique Identifier : AIDSLINE
       MED/94284639
 AB    Better markers for determining therapeutic efficacy of antiretroviral
       drugs are needed for human immunodeficiency virus (HIV) infection. The
       amounts of unintegrated HIV DNA (uDNA) were sequentially determined in
       peripheral blood mononuclear cells (PBMC) from 20 HIV-infected patients
       starting nucleoside therapy. HIV copy number was determined using a
       quantitative polymerase chain reaction assay. Before therapy, 19 of 20
       patients had detectable HIV uDNA. The average percentage of uDNA was
       42%. After 1, 4, and 8 weeks of nucleoside therapy the average decreased
       to 23% (P < .001), 7%, and 3%, respectively. The amount of HIV uDNA
       decreased in all 19 patients during the first week and was undetectable
       in 14 by 8 weeks. Thus, measurement of HIV uDNA has many characteristics
       needed for a good marker of therapeutic efficacy of antiretroviral
       drugs, including detectability in a high proportion of patients, large
       and rapid response to initiation of therapy, and a biologically
       plausible mechanism.
 DE    Adult  DNA, Viral/*METABOLISM  Genetic Markers  Human  HIV
       Infections/*DRUG THERAPY/MICROBIOLOGY  HIV-1/*GENETICS
       Nucleosides/*THERAPEUTIC USE  Polymerase Chain Reaction  Prospective
       Studies  Support, Non-U.S. Gov't  Virus Integration  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).